These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31611133)

  • 1. Aluminum and vaccines: Current state of knowledge.
    Goullé JP; Grangeot-Keros L
    Med Mal Infect; 2020 Feb; 50(1):16-21. PubMed ID: 31611133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. About the alleged toxicity of aluminium-based adjuvants in vaccines: All published studies should be taken into account.
    Goullé JP; Couvreur P; Grangeot-Keros L
    Int J Pharm; 2021 Jun; 602():120656. PubMed ID: 33932540
    [No Abstract]   [Full Text] [Related]  

  • 3. Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system.
    Gherardi RK; Crépeaux G; Authier FJ
    Autoimmun Rev; 2019 Jul; 18(7):691-705. PubMed ID: 31059838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome].
    Gherardi RK
    Rev Neurol (Paris); 2003 Feb; 159(2):162-4. PubMed ID: 12660567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome.
    Exley C; Swarbrick L; Gherardi RK; Authier FJ
    Med Hypotheses; 2009 Feb; 72(2):135-9. PubMed ID: 19004564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aluminium adjuvant exposure through vaccines in France in 2018].
    Angrand L; Elnar AA; Authier FJ; Gherardi RK; Crépeaux G
    Ann Pharm Fr; 2020 Mar; 78(2):111-128. PubMed ID: 32081303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aluminum adjuvants of vaccines injected into the muscle: Normal fate, pathology and associated disease.
    Gherardi RK; Aouizerate J; Cadusseau J; Yara S; Authier FJ
    Morphologie; 2016 Jun; 100(329):85-94. PubMed ID: 26948677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.
    Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z
    J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.
    Willhite CC; Karyakina NA; Yokel RA; Yenugadhati N; Wisniewski TM; Arnold IM; Momoli F; Krewski D
    Crit Rev Toxicol; 2014 Oct; 44 Suppl 4(Suppl 4):1-80. PubMed ID: 25233067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vaccine adjuvants and macrophagic myofasciitis].
    Siegrist CA
    Arch Pediatr; 2005 Jan; 12(1):96-101. PubMed ID: 15653065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice.
    Freiberger SN; Leuthard DS; Duda A; Contassot E; Thallmair M; Kündig TM; Johansen P
    Eur J Pharm Sci; 2018 Mar; 115():362-368. PubMed ID: 29410031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical analysis of reference studies on the toxicokinetics of aluminum-based adjuvants.
    Masson JD; Crépeaux G; Authier FJ; Exley C; Gherardi RK
    J Inorg Biochem; 2018 Apr; 181():87-95. PubMed ID: 29307441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vaccine adjuvants and macrophagic myofasciitis].
    Siegrist CA
    Bull Acad Natl Med; 2003; 187(8):1511-8; discussion 1519-21. PubMed ID: 15146582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aluminum inclusion macrophagic myofasciitis: a recently identified condition.
    Gherardi RK; Authier FJ
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):699-712. PubMed ID: 14753387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity.
    Shaw CA; Tomljenovic L
    Immunol Res; 2013 Jul; 56(2-3):304-16. PubMed ID: 23609067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA).
    Ameratunga R; Gillis D; Gold M; Linneberg A; Elwood JM
    J Allergy Clin Immunol Pract; 2017; 5(6):1551-1555.e1. PubMed ID: 28888842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aluminum as an adjuvant in vaccines and post-vaccine reactions].
    Fiejka M; Aleksandrowicz J
    Rocz Panstw Zakl Hig; 1993; 44(1):73-80. PubMed ID: 8235346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy?
    Shaw CA; Li D; Tomljenovic L
    Immunotherapy; 2014; 6(10):1055-71. PubMed ID: 25428645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adjuvant aluminum fate - Metabolic tale based on the basics of chemistry and biochemistry.
    Ćirović A; Ćirović A; Nikolić D; Ivanovski A; Ivanovski P
    J Trace Elem Med Biol; 2021 Dec; 68():126822. PubMed ID: 34333362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations.
    Tomljenovic L; Shaw CA
    Lupus; 2012 Feb; 21(2):223-30. PubMed ID: 22235057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.